関連ニュース

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental

Alkermes (NASDAQ: ALKS - Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Alkermes to post earnings of ($0.04) per share and r